JP2021120380A - がんのネオエピトープ - Google Patents
がんのネオエピトープ Download PDFInfo
- Publication number
- JP2021120380A JP2021120380A JP2021072238A JP2021072238A JP2021120380A JP 2021120380 A JP2021120380 A JP 2021120380A JP 2021072238 A JP2021072238 A JP 2021072238A JP 2021072238 A JP2021072238 A JP 2021072238A JP 2021120380 A JP2021120380 A JP 2021120380A
- Authority
- JP
- Japan
- Prior art keywords
- neoepitope
- cancer
- patient
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 118
- 201000011510 cancer Diseases 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 81
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 54
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 238000001914 filtration Methods 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 238000000126 in silico method Methods 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 9
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 7
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 27
- 210000000822 natural killer cell Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000007790 solid phase Substances 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 108010073807 IgG Receptors Proteins 0.000 claims description 9
- 102000009490 IgG Receptors Human genes 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 230000009824 affinity maturation Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 238000002823 phage display Methods 0.000 claims description 5
- 238000012070 whole genome sequencing analysis Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 108700010039 chimeric receptor Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 238000002619 cancer immunotherapy Methods 0.000 claims description 3
- 238000004091 panning Methods 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 238000007482 whole exome sequencing Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000012405 in silico analysis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011222 transcriptome analysis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100035988 60S ribosomal protein L39 Human genes 0.000 description 2
- 102220569885 Cytochrome c oxidase subunit 2_M29K_mutation Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000716179 Homo sapiens 60S ribosomal protein L39 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- -1 iodoacetyl groups Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000007704 wet chemistry method Methods 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/20—Screening of libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Library & Information Science (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Description
>254 NM_001000.3 RPL39 Missense p.M29K A->T Normal: WIRMKTGNK, AF: 0.179104477612 TPM: 1023.96 TPM_MEDIAN: 7.35 LL: 183.395820896 netMHC: 242.96 Allele: HLA-A0301 WIRKKTGNK
であってよい。
Claims (49)
- がん免疫療法のための薬剤を生成する方法であって、
少なくとも1つの患者特異的及びがん特異的ながんネオエピトープを含有する複数のn‐mer体をインシリコで生成するために腫瘍についての適合する正常オミクスデータを使用するステップと、
前記n‐mer体をインシリコでフィルタリングし、そのようにしてネオエピトープ配列のサブセットを得るステップと、
前記ネオエピトープ配列のサブセットからの配列情報を使用して少なくとも1つの合成n‐merペプチドを調製するステップと、
組換え抗体を単離するために前記合成n‐merペプチドを使用するステップと、
前記組換え抗体の相補性決定領域の配列情報を得るステップと、
前記組換え抗体の相補性決定領域の配列情報を使用して合成抗体を生成するステップと、
前記合成抗体を治療剤又は診断薬に連結し、そのようにして薬剤を得るステップと
を含んでなる方法。 - 前記適合する正常オミクスデータは、全ゲノム配列決定データ、エクソーム配列決定データ、及びトランスクリプトームデータのうちの少なくとも1つである、請求項1に記載の方法。
- 前記適合する正常オミクスデータは、患者の治療の前の正常なものと照合される、請求項1に記載の方法。
- 前記複数のn‐merペプチドはそれぞれ7〜11アミノ酸の長さを有している、請求項1に記載の方法。
- 前記複数のn‐merペプチドは少なくとも1,000個のn‐merペプチドである、請求項1に記載の方法。
- 前記複数のn‐merペプチドのうちの異なるものは異なるネオエピトープを有している、請求項1に記載の方法。
- 前記フィルタリングのステップは、突然変異の種類によるフィルタリング、発現の強さによるフィルタリング、細胞内の位置によるフィルタリング、及び患者のHLA型への結合親和性によるフィルタリングのうちの少なくとも1つを含む、請求項1に記載の方法。
- 前記フィルタリングのステップは、突然変異の種類によるフィルタリング、発現の強さによるフィルタリング、細胞内の位置によるフィルタリング、及び患者のHLA型への結合親和性によるフィルタリングのうちの少なくとも2つを含む、請求項1に記載の方法。
- 前記フィルタリングのステップは、突然変異の種類によるフィルタリング、発現の強さによるフィルタリング、細胞内の位置によるフィルタリング、及び患者のHLA型への結合親和性によるフィルタリングのうちの少なくとも3つを含む、請求項1に記載の方法。
- 組換え抗体を単離するために前記合成n‐merペプチドを使用するステップは、ファージパニングを含んでなる、請求項1に記載の方法。
- 前記ファージパニングのステップは、親和性成熟をさらに含んでなる、請求項10に記載の方法。
- 前記組換え抗体の相補性決定領域の配列情報は、CDR1‐H、CDR2‐H、及びCDR3‐Hを含んでなる、請求項1に記載の方法。
- 前記合成抗体は、ヒト抗体の足場上へのCDR又はSDRのグラフティングを使用して生成される、請求項1に記載の方法。
- 前記合成抗体は、組換え発現によってIgG、F(ab’)2、Fab’、Fab、又はscFvとして生成される、請求項1に記載の方法。
- 前記治療剤又は診断薬は非細胞性の作用物質である、請求項1に記載の方法。
- 前記非細胞性の作用物質は、化学療法薬、放射性同位体、PETで検出可能な同位体、SPECTで検出可能な同位体、又は親和性作用物質である、請求項15に記載の方法。
- 前記治療剤は細胞である、請求項1に記載の方法。
- 前記細胞はT細胞又はNK細胞である、請求項17に記載の方法。
- 前記細胞は、エクトドメインとしてscFvを有するキメラ受容体を発現するT細胞であり、前記合成抗体はscFvである、請求項18に記載の方法。
- 前記細胞は、高親和性のFcγ受容体(CD16)を発現するNK細胞であり、前記合成抗体はIgGであって、かつ、高親和性のFcγ受容体を介してNK細胞に結合される、請求項18に記載の方法。
- 前記薬剤は、適合する正常オミクスデータの使用から6週間未満以内に治療上有効な量で得られる、請求項1に記載の方法。
- 患者のがんネオエピトープが防御免疫応答を誘発しなかった場合にがんネオエピトープに対する合成抗体を生成する方法であって、
組換え抗体のライブラリから結合性の組換え抗体を選択するためにがんネオエピトープを使用するステップであって、前記がんネオエピトープが患者特異的及びがん特異的であるステップと、
前記結合性の組換え抗体の超可変ループを分析することによって前記結合性の組換え抗体に関する特異性の情報を得るステップと、
前記特異性の情報を使用して、ヒト抗体の少なくとも一部分をコードする遺伝子を改変するステップと、
前記合成抗体を生産するために改変遺伝子を組換え発現するステップと
を含んでなる方法。 - 前記がんネオエピトープは、HLAが適合するがんネオエピトープである、請求項22に記載の方法。
- 前記組換え抗体のライブラリは、ファージディスプレイライブラリである、請求項22に記載の方法。
- 最適化された結合性の組換え抗体を導き出すために前記結合性の組換え抗体の親和性成熟を行うステップをさらに含んでなる、請求項22に記載の方法。
- 前記超可変ループを分析する分析するステップは、前記超可変ループをコードするDNAを配列決定することを含んでなる、請求項22に記載の方法。
- 前記改変するステップは、CDR又はSDRのグラフティングを含んでなる、請求項22に記載の方法。
- 前記ヒト抗体の少なくとも一部分はscFvである、請求項22に記載の方法。
- 前記遺伝子を組換え発現するステップは、IgG、F(ab’)2、Fab’、Fab、又はscFvの形態で合成抗体を生産する、請求項22に記載の方法。
- 前記がんネオエピトープは、患者のがんにおいて発現されている、請求項22に記載の方法。
- 前記ネオエピトープは患者及び患者のがんに特有のものである、請求項22に記載の方法。
- がんに特異的でさらに患者に特異的なHLAが適合するがんネオエピトープに対して結合親和性を有する合成抗体を含んでなる組成物であって、前記HLAが適合するがんネオエピトープは、患者に特有でかつ患者のがんに特有のものである、組成物。
- 前記HLAが適合するがんネオエピトープは、MHC‐I提示について適合している、請求項32に記載の組成物。
- 前記合成抗体は、IgG、F(ab’)2、Fab’、Fab、及びscFvのうちから選択される、請求項32に記載の組成物。
- 前記合成抗体には治療剤が連結されている、請求項32に記載の組成物。
- 前記治療剤は非細胞性の作用物質である、請求項35に記載の組成物。
- 前記非細胞性の作用物質は、化学療法薬、放射性同位体、PETで検出可能な同位体、SPECTで検出可能な同位体、又は親和性作用物質である、請求項36に記載の組成物。
- 前記治療剤は細胞である、請求項35に記載の組成物。
- 前記細胞はT細胞であるか、あるいは遺伝子改変されたCD16受容体をオプションで発現するNK細胞である、請求項38に記載の組成物。
- 前記細胞は、エクトドメインとしてscFvを有するキメラ受容体を発現するT細胞であり、前記合成抗体はscFvである、請求項39に記載の組成物。
- 前記細胞は、高親和性のFcγ受容体(CD16)を発現するNK細胞であり、前記合成抗体はIgGであって、かつ、高親和性のFcγ受容体を介してNK細胞に結合される、請求項39に記載の組成物。
- 前記HLAが適合するがんネオエピトープは、配列番号1〜配列番号1,408,729のうちから選択される配列を有する、請求項32に記載の組成物。
- がんに特異的でさらに患者に特異的なHLAが適合するがんネオエピトープが結合した固相を含んでなる組成物であって、前記HLAが適合するがんネオエピトープは、患者に特有でかつ患者のがんに特有のものである、組成物。
- 前記固相は、試薬容器の内壁、磁気ビーズ、又は個々にアドレス可能な要素を含んでなる、請求項43に記載の組成物。
- 前記HLAが適合するがんネオエピトープは、7〜9アミノ酸の長さを有する、請求項43に記載の組成物。
- 前記HLAが適合するがんネオエピトープに結合した合成抗体をさらに含んでなる、請求項43に記載の組成物。
- 結合している前記合成抗体は、IgG、F(ab’)2、Fab’、Fab、及びscFvのうちから選択される、請求項46に記載の組成物。
- 前記合成抗体はウイルス粒子に連結されている、請求項46に記載の組成物。
- 前記HLAが適合するがんネオエピトープは、配列番号1〜配列番号1,408,729のうちから選択される配列を有する、請求項46に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562178956P | 2015-04-23 | 2015-04-23 | |
US62/178,956 | 2015-04-23 | ||
US201562159145P | 2015-05-08 | 2015-05-08 | |
US62/159,145 | 2015-05-08 | ||
JP2017555492A JP7236216B2 (ja) | 2015-04-23 | 2016-04-25 | がんのネオエピトープ |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555492A Division JP7236216B2 (ja) | 2015-04-23 | 2016-04-25 | がんのネオエピトープ |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021120380A true JP2021120380A (ja) | 2021-08-19 |
Family
ID=57144677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555492A Active JP7236216B2 (ja) | 2015-04-23 | 2016-04-25 | がんのネオエピトープ |
JP2021072238A Pending JP2021120380A (ja) | 2015-04-23 | 2021-04-22 | がんのネオエピトープ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555492A Active JP7236216B2 (ja) | 2015-04-23 | 2016-04-25 | がんのネオエピトープ |
Country Status (11)
Country | Link |
---|---|
US (2) | US11421016B2 (ja) |
EP (1) | EP3286361A4 (ja) |
JP (2) | JP7236216B2 (ja) |
CN (1) | CN108513593A (ja) |
AU (1) | AU2016253145B2 (ja) |
BR (1) | BR112017022845A2 (ja) |
CA (3) | CA2988388C (ja) |
IL (1) | IL255217B (ja) |
MX (1) | MX2017013613A (ja) |
RU (1) | RU2719033C2 (ja) |
WO (1) | WO2016172722A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139257A1 (en) * | 2022-01-21 | 2023-07-27 | T-Knife Gmbh | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2970921T3 (en) | 2013-03-15 | 2019-01-14 | Atyr Pharma Inc | Histidyl-tRNA synthetase-Fc conjugates |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US20160280778A1 (en) | 2015-03-27 | 2016-09-29 | Wisconsin Alumni Research Foundation | Compositions and methods of use of interleukin-10 peptides and anti-interleukin-10 antibodies |
CA2987730C (en) | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
TWI806815B (zh) * | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
JP6873482B2 (ja) * | 2015-10-08 | 2021-05-19 | オンコセラピー・サイエンス株式会社 | Foxm1由来ペプチドおよびそれを含むワクチン |
EP3362930A4 (en) | 2015-10-12 | 2019-06-19 | Nantomics, LLC | SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS |
GB201520579D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520603D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201607535D0 (en) * | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201520559D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520557D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
CN108701172A (zh) | 2016-02-12 | 2018-10-23 | 南托米克斯有限责任公司 | 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点 |
US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
KR102356961B1 (ko) * | 2016-03-02 | 2022-01-28 | 도레이 카부시키가이샤 | 면역 유도제 |
WO2018158985A1 (ja) * | 2017-03-03 | 2018-09-07 | 学校法人藤田学園 | アレルギーの抗原およびそのエピトープ |
KR20180117227A (ko) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들 |
WO2017170926A1 (ja) * | 2016-03-31 | 2017-10-05 | 千寿製薬株式会社 | 神経保護ペプチド |
PE20181923A1 (es) * | 2016-03-31 | 2018-12-11 | Neon Therapeutics Inc | Neoantigenos y metodos de su uso |
WO2017216289A1 (en) * | 2016-06-16 | 2017-12-21 | Skiöldebrand Eva | Compeptide and antibodies thereto for diagnosing osteoarthritis |
KR20190031492A (ko) | 2016-06-30 | 2019-03-26 | 난트 홀딩스 아이피, 엘엘씨 | 난트 암 백신(nant cancer vaccine) |
GB201615746D0 (en) * | 2016-09-15 | 2016-11-02 | Nordic Bioscience As | Nidogen-1 Assay |
GB201618432D0 (en) | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
EP3323827A1 (en) | 2016-11-21 | 2018-05-23 | Christian-Albrechts-Universität zu Kiel | Cationic intrinsically disordered antimicrobial peptides |
CA3044424C (en) | 2016-11-21 | 2023-05-23 | Nant Holdings Ip, Llc | Fractal combination therapy |
WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
TW201825118A (zh) * | 2016-11-30 | 2018-07-16 | 美商艾堤爾製藥公司 | 抗-hrs抗體及用於治療癌症之組合療法 |
EP3329930A1 (en) * | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
AU2017373651B2 (en) | 2016-12-05 | 2022-03-10 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
JP7017726B2 (ja) | 2017-01-30 | 2022-02-09 | 国立研究開発法人国立循環器病研究センター | 血管内皮系細胞に特異的に結合するペプチドの使用、及びペプチド |
JP7320796B2 (ja) * | 2017-01-30 | 2023-08-04 | 国立研究開発法人国立循環器病研究センター | 血管内皮系細胞に特異的に結合するペプチドの使用、及びペプチド |
AU2018214650B2 (en) * | 2017-02-06 | 2022-04-14 | Amolyt Pharma | Compounds, compositions and uses thereof for improvement of bone disorders |
AU2018219862B2 (en) | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
WO2018156892A1 (en) * | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
SE541618C2 (en) | 2017-02-24 | 2019-11-12 | Biotome Pty Ltd | Novel peptides and their use in diagnosis |
SG11201907402SA (en) | 2017-03-03 | 2019-09-27 | Treos Bio Zrt | Population-based immunogenic peptide identification platform |
JP7252145B2 (ja) * | 2017-03-16 | 2023-04-04 | マイクロシンテシス インコーポレイテッド | プロバイオティクス分子を含む組成物および方法 |
EA201992176A1 (ru) | 2017-03-16 | 2020-03-04 | Микросинтесис Инк. | Пробиотические молекулы для снижения вирулентности патогена |
CN110799196B (zh) * | 2017-03-31 | 2024-02-13 | 行动基因(智财)有限公司 | 致免疫性的癌症特异抗原决定位的排名*** |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
CN116983395A (zh) * | 2017-04-24 | 2023-11-03 | 河谷细胞有限公司 | 靶向性新表位载体及其方法 |
WO2018206535A1 (en) * | 2017-05-08 | 2018-11-15 | Novozymes A/S | Carbohydrate-binding domain and polynucleotides encoding the same |
JP2020521807A (ja) | 2017-05-09 | 2020-07-27 | ブイアイビー ブイゼットダブリュVib Vzw | 細菌感染を処置するための手段および方法 |
EP3631471A4 (en) * | 2017-05-30 | 2021-06-30 | Nant Holdings IP, LLC | ENRICHMENT OF CIRCULATING TUMOR CELLS USING NEO-EPITOPIA |
JP2020532957A (ja) * | 2017-08-10 | 2020-11-19 | グッド ティー セルズ、 インコーポレイテッド | 癌治療のためのt細胞の活性化方法 |
BR112020004869A2 (pt) * | 2017-09-12 | 2020-09-15 | Wisconsin Alumni Research Foundation | peptídeo do receptor-2 de interleucina-10, anticorpos, composições, e métodos de uso dos mesmos |
JP7045042B2 (ja) * | 2017-11-21 | 2022-03-31 | 尚史 三輪 | ヒト癌細胞転移阻害薬およびヒト癌細胞判定薬 |
US20200354730A1 (en) * | 2017-11-27 | 2020-11-12 | Nantcell, Inc. | Improved Yeast Polytope Vaccine Compositions And Methods |
US11773187B2 (en) | 2018-01-17 | 2023-10-03 | Nantbio, Inc. | Enhanced immunogenicity for GPI-anchored antigens |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
CN108484733B (zh) * | 2018-03-01 | 2021-06-25 | 国家纳米科学中心 | 双亲性靶向穿膜肽及其自组装的纳米探针、载药纳米颗粒 |
WO2019195766A1 (en) * | 2018-04-06 | 2019-10-10 | AMMA Therapeutics, Inc. | Composition for controlled release of therapeutic agents |
US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
WO2019197675A1 (en) * | 2018-04-13 | 2019-10-17 | Argenx Bvba | Galectin-10 antibodies |
KR102234027B1 (ko) * | 2018-05-09 | 2021-03-31 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도 |
JP2021524283A (ja) * | 2018-05-17 | 2021-09-13 | イムノーム、インコーポレイテッド | Ch3ドメインエピトープタグ |
MA52870A (fr) * | 2018-06-13 | 2021-04-21 | Acraf | Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3 |
US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
WO2020012478A2 (en) | 2018-07-11 | 2020-01-16 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
EP3820885A4 (en) | 2018-07-11 | 2022-04-20 | The Brigham & Women's Hospital, Inc. | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER |
EP3827262A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
US20210213116A1 (en) | 2018-07-26 | 2021-07-15 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
EP3827266A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
WO2020022903A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
CA3106573A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
SG11202101888YA (en) | 2018-09-04 | 2021-03-30 | Treos Bio Ltd | Peptide vaccines |
GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
US11884749B2 (en) | 2018-11-21 | 2024-01-30 | Endomet Biosciences, Inc. | Compositions and methods for treating endometriosis |
US20210371463A1 (en) * | 2018-12-12 | 2021-12-02 | The Regents Of The University Of California | Modified Netrin-1 Peptides and Compositions for Cardioprotection |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
JP7420361B2 (ja) * | 2019-02-25 | 2024-01-23 | 公立大学法人山陽小野田市立山口東京理科大学 | アミロイド線維の形成を抑制するペプチド |
CN111533795B (zh) * | 2019-03-12 | 2020-10-30 | 上海交通大学医学院附属新华医院 | Hla-a2限制性膀胱癌肿瘤新抗原肽序列及其应用 |
EP3941932A1 (en) * | 2019-03-21 | 2022-01-26 | Institute for Research in Biomedicine | Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof |
WO2020205778A1 (en) * | 2019-03-30 | 2020-10-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
EP3959233A4 (en) * | 2019-04-25 | 2023-04-19 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | NETRIN G1 AND NETRIN G1 LIGAND PEPTIDES AND ANTIBODIES AND THEIR USES |
EP3763725A1 (en) | 2019-07-08 | 2021-01-13 | TCI Co., Ltd. | Biomimetic peptides derived from biological source and their uses in retarding aging and improving skin |
US20220289866A1 (en) * | 2019-07-12 | 2022-09-15 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
BR112022003790A2 (pt) * | 2019-09-02 | 2022-05-31 | Inst Nat Sante Rech Med | Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes |
CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及*** |
EP4063378A4 (en) * | 2019-11-21 | 2024-06-19 | Shanghai Institute of Pharmaceutical Industry Co., Ltd. | BIOLOGICAL PEPTIDE FOR THE TREATMENT OF LUNG DISEASES AND ITS USE |
MX2019014546A (es) * | 2019-12-04 | 2023-01-10 | Univ Mexico Nac Autonoma | Péptido con actividad anti-cáncer. |
CN115279400A (zh) | 2020-01-10 | 2022-11-01 | 布里格姆妇女医院 | 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物 |
IL272074A (en) * | 2020-01-15 | 2021-07-29 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
IT202000019708A1 (it) * | 2020-08-07 | 2022-02-07 | Ospedale Pediatrico Bambino Gesù | Peptidi in grado di legare il recettore enzima di conversione dell'angiotensina 2 (ACE2) e loro usi medici |
CN111978375B (zh) * | 2020-08-28 | 2022-10-04 | 深圳市乐土生物医药有限公司 | 具有细胞毒性t细胞诱导能力的蛋白质或多肽 |
WO2022094139A1 (en) * | 2020-10-28 | 2022-05-05 | Ohio State Innovation Foundation | Peptide inhibitors for the treatment and prevention of coronavirus infections |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
EP4247401A1 (en) * | 2020-11-20 | 2023-09-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
WO2022120423A1 (en) * | 2020-12-08 | 2022-06-16 | James Cook University | Peptides and uses thereof |
WO2022133074A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Muc1 binding molecules and uses thereof |
EP4281565A1 (en) * | 2021-01-22 | 2023-11-29 | Syngenta Crop Protection AG | Soybean engineered resistance |
EP4311399A2 (en) * | 2021-03-10 | 2024-01-31 | The Board Of Regents Of The University Of Oklahoma | Self-assembling peptides, nanofibers, and methods of use |
JP2023522311A (ja) * | 2021-03-22 | 2023-05-30 | エル-ベース カンパニー リミテッド | がんの予防または治療用薬学的組成物 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
CA3227687A1 (en) * | 2021-08-06 | 2023-02-09 | Marc Andrew GILLIG | Process for producing personalized cancer immunotherapy |
CN115340592B (zh) * | 2021-09-09 | 2024-07-09 | 禾美生物科技(浙江)有限公司 | 一种活性肽及其相关用途 |
WO2023150705A2 (en) * | 2022-02-04 | 2023-08-10 | Hofseth Biocare Asa | Upregulation of ferritin heavy chain 1 expression |
AU2023218551A1 (en) * | 2022-02-09 | 2024-08-01 | Teitur Trophics Aps | Novel peptides |
WO2023161443A1 (en) * | 2022-02-25 | 2023-08-31 | Institut Curie | PEPTIDES TARGETING THE INTERACTION BETWEEN KINDLIN-1 AND ß-INTEGRIN |
WO2023187127A1 (en) * | 2022-03-31 | 2023-10-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
WO2023220688A1 (en) * | 2022-05-11 | 2023-11-16 | The Johns Hopkins University | Engineering of multifunctional peptides for controlled drug delivery |
WO2023244919A1 (en) * | 2022-06-16 | 2023-12-21 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment |
WO2024030976A2 (en) * | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
WO2024076285A1 (en) * | 2022-10-05 | 2024-04-11 | Ivarsson Ylva | Peptide targeting sars-cov-2 nsp9 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2338515A3 (en) | 2000-02-10 | 2011-11-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
EP1461001A4 (en) | 2002-01-03 | 2010-03-31 | Scripps Research Inst | EPITOPE ASSOCIATED WITH CANCER |
US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
WO2005019432A2 (en) | 2003-08-20 | 2005-03-03 | Cleveland Clinic Foundation Innovations | A novel gene and protein associated with angiogenesis and endothelial apoptosis |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
WO2006040322A1 (en) | 2004-10-12 | 2006-04-20 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
US7811993B2 (en) * | 2005-06-29 | 2010-10-12 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
BRPI0718197A2 (pt) | 2006-10-02 | 2014-09-30 | Medarex Inc | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo. |
JP5398545B2 (ja) | 2007-01-05 | 2014-01-29 | ユニバーシティ・オブ・チューリッヒ | 疾病に特異的な結合分子および標的を提供する方法 |
JP5948319B2 (ja) | 2010-05-14 | 2016-07-06 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
EP2577538A1 (en) | 2010-05-25 | 2013-04-10 | The Regents of the University of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US9646134B2 (en) * | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
JP2013235003A (ja) | 2012-05-10 | 2013-11-21 | Fujita Gakuen | 細胞におけるdna損傷の検出方法及びdna鎖切断応答性細胞表面抗原に対する抗体 |
EP2850102A1 (en) | 2012-05-15 | 2015-03-25 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US10501801B2 (en) * | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
CA2908434C (en) | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2014197871A2 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
US20160258025A1 (en) | 2013-10-18 | 2016-09-08 | The Regents Of The University Of California | Predicting patient responsiveness to immune checkpoint inhibitors |
JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
CN106164289A (zh) * | 2014-01-02 | 2016-11-23 | 纪念斯隆凯特琳癌症中心 | 癌症对免疫疗法的反应的决定因素 |
CA2987730C (en) | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
JP2018524284A (ja) * | 2015-05-18 | 2018-08-30 | ユーリカ セラピューティックス, インコーポレイテッド | 抗ror1抗体 |
-
2016
- 2016-04-25 WO PCT/US2016/029244 patent/WO2016172722A1/en active Application Filing
- 2016-04-25 US US15/568,487 patent/US11421016B2/en active Active
- 2016-04-25 BR BR112017022845-9A patent/BR112017022845A2/pt active Search and Examination
- 2016-04-25 MX MX2017013613A patent/MX2017013613A/es unknown
- 2016-04-25 CA CA2988388A patent/CA2988388C/en active Active
- 2016-04-25 CA CA3172682A patent/CA3172682A1/en active Pending
- 2016-04-25 CN CN201680037507.1A patent/CN108513593A/zh active Pending
- 2016-04-25 CA CA3172686A patent/CA3172686A1/en active Pending
- 2016-04-25 AU AU2016253145A patent/AU2016253145B2/en active Active
- 2016-04-25 EP EP16784102.2A patent/EP3286361A4/en active Pending
- 2016-04-25 JP JP2017555492A patent/JP7236216B2/ja active Active
- 2016-04-25 RU RU2017145136A patent/RU2719033C2/ru active
-
2017
- 2017-10-23 IL IL255217A patent/IL255217B/en unknown
-
2021
- 2021-04-22 JP JP2021072238A patent/JP2021120380A/ja active Pending
-
2022
- 2022-06-17 US US17/843,247 patent/US20220403007A1/en active Pending
Non-Patent Citations (3)
Title |
---|
CANCER IMUNOL RES, 2014, 2(6), PP.522-529, JPN6020013680, ISSN: 0004787523 * |
SCIENCE, 2006, VOL. 314, PP.304-308, JPN6020013682, ISSN: 0004787524 * |
生物物理、2008、48(5)、PP.294-298, JPN6020013683, ISSN: 0004787525 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139257A1 (en) * | 2022-01-21 | 2023-07-27 | T-Knife Gmbh | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
Also Published As
Publication number | Publication date |
---|---|
US11421016B2 (en) | 2022-08-23 |
WO2016172722A1 (en) | 2016-10-27 |
CA3172686A1 (en) | 2016-10-27 |
JP7236216B2 (ja) | 2023-03-09 |
CA3172682A1 (en) | 2016-10-27 |
US20220403007A1 (en) | 2022-12-22 |
IL255217B (en) | 2021-12-01 |
JP2018513187A (ja) | 2018-05-24 |
EP3286361A1 (en) | 2018-02-28 |
AU2016253145A1 (en) | 2018-01-04 |
CA2988388A1 (en) | 2016-10-27 |
RU2017145136A (ru) | 2019-06-21 |
CN108513593A (zh) | 2018-09-07 |
RU2719033C2 (ru) | 2020-04-16 |
US20180141998A1 (en) | 2018-05-24 |
IL255217A0 (en) | 2017-12-31 |
AU2016253145B2 (en) | 2020-07-02 |
RU2017145136A3 (ja) | 2019-09-13 |
EP3286361A4 (en) | 2019-05-08 |
BR112017022845A2 (pt) | 2018-07-17 |
MX2017013613A (es) | 2018-09-12 |
CA2988388C (en) | 2022-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021120380A (ja) | がんのネオエピトープ | |
US20230293651A1 (en) | Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor | |
ES2541934T3 (es) | Métodos para la identificación de un anticuerpo o una diana | |
JP2018530579A (ja) | ウイルス性癌ネオエピトープのための組成物および方法 | |
JP6991967B2 (ja) | ウイルスネオエピトープおよびその使用 | |
WO2020077128A1 (en) | Tumor hla mutation versus matched normal hla | |
WO2023086824A1 (en) | Methods for identification of antigen-binding molecules | |
WO2023201235A2 (en) | Compositions and methods for generating and characterizing recombinant antigen binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210521 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210521 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220831 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230405 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230405 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230418 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230523 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230616 |